UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 5, 2016
Atara Biotherapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware |
|
001-36548 |
|
46-0920988 |
|
(State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer Identification No.) |
|
611 Gateway Blvd., Suite 900 South San Francisco, CA |
|
94080 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (650) 278-8930
701 Gateway Boulevard, Suite 200
South San Francisco, CA 94080
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition.
On May 5, 2016, Atara Biotherapeutics, Inc. (“Atara”) announced certain financial results for the first quarter March 31, 2016. A copy of Atara’s press release, titled “Atara Bio Announces First Quarter 2016 Financial Results and Recent Highlights” is furnished as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1Press Release, dated May 5, 2016, titled “Atara Bio Announces First Quarter 2016 Financial Results and Recent Highlights.”
The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this report and the attached Exhibit 99.1 shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
Atara Biotherapeutics, Inc. |
||
|
(Registrant)
|
||
|
|
|
|
|
By: |
|
/s/ Heather Turner |
|
|
|
Heather Turner |
|
|
|
Vice President, General Counsel & Secretary |
Date: May 5, 2016
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release, dated May 5, 2016, titled “Atara Bio Announces First Quarter 2016 Financial Results and Recent Highlights.” |